Head-to-head evidence
Gemigliptin vs Linagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Gemigliptin · Zemiglo
Developed by LG Chem
NCT01787396 · Phase 3 · completed
This was a randomized, quadruple-blind trial (n=433) with three arms: gemigliptin plus metformin, gemigliptin alone (with a matching metformin placebo), and metformin alone (with a matching gemigliptin placebo). The primary endpoint, HbA1c change at 24 weeks, favored the combination over either monotherapy.
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gemigliptin's landscape · Linagliptin's landscape